Recent Activity

Loading...

GERN

Geron Corporation · NASDAQ

Performance

-6.52%

1W

+16.57%

1M

+104.76%

3M

+109.19%

6M

+83.41%

YTD

+40.73%

1Y

Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Investment Analysis Report: GERN

Overview

In this investment analysis report, we will delve into a comprehensive analysis of GERN, a company operating in the Health Technology sector within the Biotechnology industry. We will focus on various aspects including Valuation, Financial Health, Earnings and Revenue Growth, Profitability, Operating Mar...

See more ...

Technical Analysis of GERN 2024-05-03

Overview:

In analyzing the technical indicators for GERN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for potential in...

See more ...

Recent News & Updates